NCT00628420View on ClinicalTrials.gov

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

October 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

ACP-104

25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks

DRUG

ACP-104

Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks

DRUG

Placebo

patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.

Trial Locations (2)

75216

Veteran's Affairs Medical Center, Dallas

75390

The University of Texas Southwestern Medical Center, Dallas

Sponsors
All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

collaborator

ACADIA Pharmaceuticals Inc.

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER